Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Subject collections
    • Interviews
    • Alerts
  • About us
    • About DMM
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Workshops and Meetings
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Outstanding paper prize
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Alerts
  • Contact
    • Contact DMM
    • Advertising
    • Feedback
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

User menu

  • Log in

Search

  • Advanced search
Disease Models & Mechanisms
  • COB
    • About The Company of Biologists
    • Development
    • Journal of Cell Science
    • Journal of Experimental Biology
    • Disease Models & Mechanisms
    • Biology Open

supporting biologistsinspiring biology

Disease Models & Mechanisms

Advanced search

RSS   Twitter   Facebook   YouTube

  • Home
  • Articles
    • Accepted manuscripts
    • Issue in progress
    • Latest complete issue
    • Issue archive
    • Archive by article type
    • Subject collections
    • Interviews
    • Alerts
  • About us
    • About DMM
    • Editors and Board
    • Editor biographies
    • Travelling Fellowships
    • Grants and funding
    • Workshops and Meetings
    • The Company of Biologists
    • Journal news
  • For authors
    • Submit a manuscript
    • Aims and scope
    • Presubmission enquiries
    • Article types
    • Manuscript preparation
    • Cover suggestions
    • Editorial process
    • Promoting your paper
    • Open Access
    • Outstanding paper prize
    • Biology Open transfer
  • Journal info
    • Journal policies
    • Rights and permissions
    • Media policies
    • Reviewer guide
    • Alerts
  • Contact
    • Contact DMM
    • Advertising
    • Feedback
Commentary
mRNA nuclear export and human disease
Jessica A. Hurt, Pamela A. Silver
Disease Models & Mechanisms 2008 1: 103-108; doi: 10.1242/dmm.000745
Jessica A. Hurt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pamela A. Silver
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & tables
  • Info & metrics
  • PDF
Loading

Abstract

Export of mRNA from the nucleus is a central process in eukaryotic gene expression that has been implicated in several human diseases. Much of our understanding of how an mRNA is transported to the cytoplasm is derived from studies using yeast and fly models. We present here different mechanisms by which aberrant nuclear retention of mRNA can cause human disease. Emerging evidence that implicates the mRNA export factor GLE1 in two lethal motor neuron disorders is discussed and we highlight surprising links to regulatory mechanisms that were first observed many years ago in yeast. These examples illustrate how model organisms have aided in our elucidation of complex human disorders through analysis of basic cellular processes.

In eukaryotic cells, gene expression requires efficient and proper transport of mRNAs from the nucleus to the cytoplasm. Studies performed in model organisms have provided the groundwork for our understanding of mRNA nuclear export and have highlighted many mRNA maturation events that influence the export of messages to the cytoplasm. Here we briefly discuss the nuclear mRNA processing steps that are integrated with mRNA export and, through discussion of three disorders – osteogenesis imperfecta (OI) type I, myotonic dystrophy (DM) type 1 and lethal congenital contracture syndrome 1 (LCCS1) – describe how defects in the export pathway can result in disease. We emphasize the roles that model organisms, particularly the yeast Saccharomyces cerevisiae and the fly Drosophila melanogaster, have played in our comprehension of the export process relative to these disorders. Given the ease of experimental utility and the wealth of knowledge of the mRNA export pathway that S. cerevisiae and Drosophila have provided, we envisage their continued importance in elucidating the molecular pathology and therapeutic development of such disorders.

Model organisms have provided the framework for our understanding of mRNA export

Extensive work in model organisms has illustrated that, in addition to specific messenger ribonucleoprotein particle (mRNP) receptor complexes and the nuclear pore components with which they interact, mRNA export events are also highly coupled to nuclear mRNA maturation steps. The importance of intact splicing and 3′ processing signals, and modifications, such as 5′ capping, in mRNA export were initially discovered by assessing the subcellular localization of mutant pre-mRNA transcripts transformed into yeast or mammalian cells, or injected into Xenopus oocytes (Chang and Sharp, 1989; Eckner et al., 1991; Hamm and Mattaj, 1990; Legrain and Rosbash, 1989). Larger scale investigation of components required for mRNA export began in yeast, where temperature-sensitive libraries were used to identify factors that, when mutated, resulted in aberrant accumulation of polyadenylated [poly(A)] RNA in the nucleus (Amberg et al., 1992; Kadowaki et al., 1992). Furthermore, studies in yeast and metazoans have revealed that disruption of factors involved in nuclear mRNA processing events, including splicing, 3′ processing and surveillance, triggers mRNA nuclear retention (Brodsky and Silver, 2000; Farny et al., 2008; Gatfield et al., 2001; Hammell et al., 2002; Hieronymus et al., 2004; Strasser and Hurt, 2001).

The importance of the mRNA export pathway to cellular function is exemplified by both its conservation and adaptation between organisms. Many factors required for export in lower eukaryotes have since been shown to be similarly required for mRNA export in human cells (Guzik et al., 2001; Kapadia et al., 2006; van Deursen et al., 1996; Watkins et al., 1998; Williams et al., 2005). A recent genome-wide screen for export factors found that the complexity of the fly mRNA export pathway reflects the degree of transcript structure of the organism (Farny et al., 2008). The fact that an organism with a more involved transcript maturation program requires a more complicated mRNA export network suggests that higher eukaryotic systems model the organization of the human mRNA export process more completely than do simpler eukaryotes.

The physical and functional coupling of the export process to nuclear mRNA processing contributes to its efficiency and fidelity (reviewed by Bentley, 2005; Luna et al., 2008; Reed, 2003; Reed and Cheng, 2005; Saguez et al., 2005; Sommer and Nehrbass, 2005). Heterodimers of Mex67 (Drosophila NXF1, sbr/human TAP) and Mtr2 (Drosophila p15/human NXT1), the proteins responsible for ferrying the majority of mRNAs across the pore, have an inherently low affinity for mRNA (Braun et al., 1999). These heterodimers interface with transcripts through interactions with adaptor proteins [such as Yra1 (Drosophila/human Aly), see below] that coat mRNPs. Thus, one mechanism to ensure export of only fully mature mRNAs is to recruit Mex67/Mtr2 to RNA through adaptor proteins responsible for completion of distinct maturation steps (Fig. 1).

Export of improperly processed transcripts is further prevented through surveillance mechanisms that retain aberrant messages at the site of transcription for subsequent degradation. How the improperly processed transcripts are recognized and retained remains largely unknown. However, studies in yeast, fly and human cells have demonstrated that mutation of some export and nuclear processing factors (Bousquet-Antonelli et al., 2000; Burkard and Butler, 2000; Hilleren et al., 2001; Libri et al., 2002; Zenklusen et al., 2002) and of transcript processing signal sequences (Custodio et al., 1999; Das et al., 2006; Muhlemann et al., 2001) can enable such surveillance mechanisms.

Fig. 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1. mRNA export is coupled to nuclear processing events, including transcription, 5′ capping, splicing and 3′-end processing.

During yeast mRNA processing, adaptor proteins, including Yra1 (blue) and other export factors, such as Dbp5 (orange), are deposited onto the maturing mRNP. mRNA transport proteins Mex67/Mtr2 (purple) interface between the mature mRNP and the nuclear pore via interactions with adaptor proteins and the FG repeats of specific nuclear pore proteins (grey). When the mRNP approaches the cytoplasmic face of the pore, InsP6 (dark pink)-bound Gle1 (teal) activates the RNA helicase activity of Dbp5. This helicase may stimulate the release of Mex67/Mtr2 from the message thus preventing re-import. Free carrier proteins are then recycled into the nucleus for the next round of transport. InsP6 is derived chiefly from InsP5 (light pink) by the activity of nuclear envelope localized InsP6 2-kinase (Ipk1, dark blue).

Defects in mRNA export can result in human disease

mRNA nuclear export defects can result from two sources: mutations in pre-mRNA sequences and mutations in export or processing factors. Here, we discuss examples of both types and relay how our knowledge of the export pathway gleaned from work in model organisms has facilitated our understanding of the pathology of these disorders (Fig. 2).

Osteogenesis imperfecta type I: mRNA mutation results in transcript retention and disease

OI, which affects 1 in 10,000 people, encompasses a group of inherited diseases resulting in increased bone fragility caused by mutation in one of the two genes encoding collagen, COL1A1 and COL1A2 (reviewed by Roughley et al., 2003). A particular patient cohort suffering from OI type I possess a splice site mutation in COL1A1, which results in a decrease in collagen production (Johnson et al., 2000; Stover et al., 1993). This mutation causes improper splicing and retention of intron 26 of COL1A1 (COL1A1+I26) pre-mRNA, which results in sequestration of the transcript in nuclear RNA processing domains – known as splicing speckles – and thus renders it unavailable for translation in the cytoplasm (Johnson et al., 2000). Prolonged localization to the speckle suggests that the aberrant mRNA is stalled at a particular stage of nuclear processing.

As mentioned previously, splicing is intimately coupled with message nuclear export. Mutations in particular splicing sequences can result in stalled spliceosomal complexes and ultimately transcript retention (Chang and Sharp, 1989; Legrain and Rosbash, 1989). Additionally, splicing factors such as Sub2 (yeast, human/fly UAP56), are required for export and in some cases, specifically to recruit export adaptor proteins such as Yra1 (yeast, human/fly Aly) (Jensen et al., 2001; Strasser and Hurt, 2001). Thus, mutation of a splice site sequence in the COL1A1 pre-mRNA could affect subsequent recruitment of export adaptors and transport out of the splicing domain en route to nuclear export (Fig. 2A).

Interestingly, examples such as OI type I, in which an abnormally spliced transcript has been shown to be retained in the nucleus, are rare. Efficient retention of such aberrant messages at transcription sites and their subsequent destruction by nuclear degradation mechanisms may prevent their detection. The escape of COL1A1+I26 from its site of transcription to splicing speckles suggests that it has bypassed some initial surveillance mechanisms and thus is not degraded efficiently (Johnson et al., 2000).

More severe forms of OI can result from missense mutations in COL1A1 and COL1A2, which generate dominant negative collagen fibril proteins. Since these mutations do not alter the nuclear processing of the message, the cell exports the aberrant transcripts and toxic protein products are translated (reviewed by Roughley et al., 2003). Conversely, the aberrant splicing event that produces COL1A1+I26 also causes a frameshift and the encoding of downstream premature stop codons. Thus, any COL1A1+I26 that does manage to escape nuclear retention is likely to be degraded by the nonsense-mediated decay (NMD) pathway in the cytoplasm. If, however, a portion of the COL1A1+I26 transcript was able to leak into the cytoplasm and was not targeted by NMD, its translation might produce dominant negative fibrils as in the more severe forms of OI. Thus in the specific case of OI type I discussed above, a combination of transcript nuclear retention and rapid cytoplasmic message decay is likely to lessen the severity of the disorder by only allowing translation of COL1A1 generated from the wild-type allele.

Myotonic dystrophy type I: toxic RNA causes nuclear retention and disease

Another human disease that results from aberrant nuclear retention of a particular mRNA is the severe muscle wasting disorder, myotonic dystrophy (DM) type I. Patients suffering from this disorder experience skeletal muscle myotonia and degeneration, which ultimately can be fatal. The most common form of DM in adults, DM type I, is an autosomal dominant disease caused by an abnormal CUG expansion in the 3′ untranslated region (UTR) of the DM protein kinase mRNA (DMPKCUG+) (reviewed by Cho and Tapscott, 2007). Toxic CUG repeats within DMPKCUG+ result in nuclear RNAs that are resistant to export. However, unlike OI type I, which results from diminished collagen production because of the decrease in exported COL1A1, DM1 does not result from decreased DMPK protein levels. Instead, the toxic RNA causes disease in trans via misregulation of splicing factors, including the muscle-blind protein family 1 (MBNL1) and CUG-binding protein 1 (CUGBP1) (Fig. 2B) (Charlet et al., 2002; Mankodi et al., 2002; Philips et al., 1998; Savkur et al., 2001) (reviewed by Wheeler and Thornton, 2007).

Fig. 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2. Defects in mRNA export can result in disease via different mechanisms.

Export adaptors or transporters and mRNA processing factors (blue) influence transcript retention (black) and export (grey). (A) Mutation of a particular mRNA can cause improper processing and its consequent inability to be recognized by the export machinery. Tissues specifically requiring expression of the encoded protein are adversely affected (OI type 1). (B) Abnormal sequence expansion in an mRNA can result in transcript nuclear retention and sequestering of trans factors (red). Tissues that are particularly sensitive to the activity of the trans factors (DM1) and/or to the levels of the encoded protein are adversely affected. The effect of sequestration of trans factors on localization of their target transcripts is largely unknown (hatched grey). (C,D) Mutation of a specific export factor (LCCS1/LAAHD) may inhibit a subset of (C) or bulk (D) message export. (C) Tissues sensitive to the levels of the proteins encoded by the retained transcripts are affected. (D) Mutation of an export factor required for bulk mRNA export could result in global inefficiency of transcript export. Tissues requiring particularly tight temporal regulation of gene expression for their differentiation, such as neurons, may be particularly susceptible to this mutation.

Normally, DMPK is transcribed at the periphery and then transported into splicing speckles before being escorted out of the nucleus as part of a mature mRNP. However, the presence of expanded CUG repeats prevents entry of the RNA into the speckle and instead, the messages accumulate in distinct foci at the periphery of the splicing domains (Holt et al., 2007; Smith et al., 2007). These foci sequester factors, such as MBNL1, which preferentially associate with the aggregates and prevent their normal nuclear activities, which in this case is the splicing of specific muscle-related transcripts (Dansithong et al., 2005). There are many factors that must associate with transcripts for export to occur and it is likely that inappropriate protein interactions with the 3′UTR repeats prevent the transcript from associating with factors of the export pathway. Interestingly, fusion of DMPKCUG+ to a viral post-transcriptional element that stimulates nucleocytoplasmic transport through a protein export pathway results in a decrease of nuclear foci and allows myoblast differentiation. Removal of the toxic foci from the nuclear compartment might at least partially diminish the disease effect (Mastroyiannopoulos et al., 2005).

Both mouse and fly disease models of DM1 have been developed and they exhibit many of the physiological and cellular phenotypes characteristic of DM1 patients, including muscle wasting, intranuclear RNA foci and splicing defects (de Haro et al., 2006; Garcia-Lopez et al., 2008; Orengo et al., 2008). A recent genetic screen in one of these Drosophila mutants identified that exacerbation of the diseased phenotype was caused by defects in the nuclear export factor Aly (Garcia-Lopez et al., 2008). As a member of the conserved REF family of mRNA export factors that interact directly with both RNA and NXF1, Aly functions as an adaptor for the recruitment of export factors to maturing mRNPs (Stutz et al., 2000) (Fig. 1). Thus, the decrease in Aly function in the DM1 study might result in a decreased capacity to export DMPKCUG+ transcripts. Given the genetic tractability of Drosophila and the fact that many of the processes shown to be important in mRNA nuclear export are likely to be conserved in humans, the development of these disease models is a powerful tool for the study and treatment of DM1.

In both diseases discussed above, we have proposed that aberrant interactions between the mutant transcripts and specific export factors result in the inability of the messages to be transported to the cytoplasm. Thus, it will be interesting to define differences in the composition of those RNA-binding proteins (RBPs) associating with both wild-type (COL1A1 and DMPK) and mutant (COL1A1+I26 and DMPKCUG+) transcripts to uncover nuclear retention mechanisms. In particular, this would provide insight into ways to promote DMPKCUG+ export and thus alleviate the resultant spliceopathies.

Lethal congenital contracture syndrome: mutation of an export factor results in disease

Recently, mutations in the mRNA export factor GLE1 were linked to two motor neuron diseases: lethal congenital contracture syndrome 1 (LCCS1) and lethal arthrogryposis with anterior horn cell disease (LAAHD) (Nousiainen et al., 2008). LCCS1 and LAAHD are rare autosomal recessive disorders and they result in fatal reductions in anterior horn motor neuron development, ventral spinal cord wasting and skeletal muscle atrophy. In these diseases, a single nucleotide substitution in intron 3 of GLE1 results in a mis-splicing event and consequently, inclusion of nine extra nucleotides in the mRNA and a three amino acid insertion into the protein sequence (Nousiainen et al., 2008).

The requirement for GLE1 in mRNA export was initially described in yeast (Gle1) (Del Priore et al., 1996; Murphy and Wente, 1996) and later in human cells (Watkins et al., 1998). Although it shuttles between the nucleus and the cytoplasm, GLE1 predominantly localizes to the cytoplasmic face of the nuclear pore complex through interactions with the nuclear pore proteins Nup155 (yeast Nup170/Nup157) and CG1 (yeast Nup42/Rip1) (reviewed by Kendirgi et al., 2005). A genetic screen for modulators of Gle1 activity led to the discovery of the enzymes required for production of the soluble inositol hexakisphosphate (InsP6) and thus sparked the hypothesis that InsP6 acts as a positive regulator of Gle1-mediated RNA export in yeast (York et al., 1999). Later it was shown that mRNA export activity in human cells also responds to nuclear InsP6 levels (Feng et al., 2001). Only recently, the direct binding of InsP6 to Gle1 was found to stimulate the RNA helicase activity of the shuttling DEAD-box mRNA export factor Dbp5 (Alcazar-Roman et al., 2006; Weirich et al., 2006). A model was proposed that at the cytoplasmic face of the nuclear pore, InsP6-bound Gle1 stimulates Dbp5 molecules that had been deposited previously onto the maturing mRNP within the nucleus. Activated Dbp5 then catalyzes the release of particular mRNP proteins required for export, such as Mex67, from the transcript (Lund and Guthrie, 2005). These newly freed export factors are recycled back into the nucleus for the next round of export (Fig. 1). Whether the LCCS1-linked mutation of GLE1 directly affects the ability of the protein to stimulate Dbp5 activity and thus mRNA export remains to be shown. However, the disease-linked insertion does interrupt the coiled-coil domain in GLE1, which might result in altered protein-protein interactions with shuttling mRNP components (Nousiainen et al., 2008).

Most interestingly, the causative mutations of two additional neonatal congenital contractural syndromes (LCCS2 and LCCS3) have been recently attributed to defects in enzymes that modulate the phosphatidylinositol-3-kinase/Akt signaling cascade, a pathway intimately connected with the production of soluble inositol phosphate molecules such as InsP 6 (Narkis et al., 2007a; 2007b). Upon first identification of these two mutations (in ERBB3 and PIP5K1C, respectively), researchers speculated that improper regulation of phosphatidylinositol bisphosphate (PIP2) and phosphatidylinositol trisphosphate (PIP3) levels, which are critical in the regulation of vesicular trafficking and cell growth and survival, could cause the pleiotropic symptoms of LCCS2 and LCCS3. Although such disruptions are still likely to be important in the pathology of these diseases, the combination of the newly identified LCCS1 mutation with our understanding of the role of the phosphorylated inositol signaling pathway in mRNA export, suggests an interesting role for mRNA export in these disorders and a relationship between inositol signaling, export and neuronal survival.

Can tissue-specific effects result from mutations in a core export factor?

As all human cells require mRNA export for proper gene expression, the mechanism underlying tissue-specific defects due to mutation of general mRNA export factors is not obvious. One explanation is that ‘general’ export factors are not so general after all (Fig. 2C). Studies in yeast and Drosophila have revealed that some factors that are seemingly required for general poly(A) RNA localization to the cytoplasm are actually regulating the export of only a subset of the transcriptome (Hieronymus and Silver, 2003; Rehwinkel et al., 2004). Perhaps GLE1 selectively affects the export of specific mRNAs. Expression array data comparing neural precursor cells derived from LCCS1 post mortem fetuses with those of controls revealed misregulation of specific mRNA species, some of which are associated with synapse and nerve development (Pakkasjarvi et al., 2007). Thus, it would be interesting to determine whether mutation of GLE1 causes mislocalization of these transcripts.

Particular tissues might also be more sensitive to the temporal regulation of gene expression for their proper differentiation (Fig. 2D). RNA in situ hybridization revealed particularly high Gle1 expression in mouse embryo ventral cells and somites: the two cell types from which motor neurons and skeletal muscle/bone, respectively, are derived (Nousiainen et al., 2008). Additionally, a study of the expression of mouse 2-kinase, responsible for production of InsP6, revealed a similar expression pattern (Verbsky et al., 2005). Enrichment of these factors in such tissues suggests particular requirements of these cells for their function. Interestingly, small bristles (sbr) (Drosophila NXF1) mutant Drosophila embryos exhibit defects in the differentiation of neurons, muscle and bristles (Korey et al., 2001). Investigators suggested that these affected tissues require extremely tight temporal control over their differentiation process and thus are more sensitive to the diminished rate of mRNA export resulting from the sbr mutation. Additionally, researchers recently suggested that spinal muscular atrophy results from specific neuronal sensitivity to levels of the spliceosome assembly component survival motor neuron (SMN) protein (Zhang et al., 2008). These data further support the idea that specific tissues have differing requirements for factors involved in ‘general’ mRNA metabolism (McKee et al., 2005).

Use of model organisms has enabled our dissection of the mRNA export pathway and preliminary comprehension of the molecular pathologies of several human diseases that result from aberrant transcript retention and export factor mutation. Complex levels of coupling between mRNA processing steps as well as transcript surveillance mechanisms, aid in the fidelity of the export process, thereby protecting the cell from production of toxic proteins while maintaining an expedient gene expression regime. As InsP 6 and its derivatives have additionally been implicated in a range of nuclear processes, including regulation of transcription, DNA repair and chromatin remodeling (reviewed by Alcazar-Roman and Wente, 2008; York, 2006), it is now important to determine how the spatial and temporal regulation of inositol phosphate signaling coordinate mRNA export with these other nuclear events.

In addition to those described here, other human disorders have been linked to mutation of export-associated factors, although the affect of their associated mutations on the fidelity of mRNA export remains largely uncharacterized (Abu-Baker and Rouleau, 2007; Nakamura, 2005). Developing models of diseases such as LCCS1 in Drosophila and other organisms that possess organ systems and signaling properties akin to humans, will be paramount to further our understanding of the relationship between mRNA export and disease. Additionally, using these models to aid in understanding the specificity that export factors have for transcripts and the tissue-specific needs for export components will be essential. Such models may also enable discovery of small molecules that regulate the mRNA export process via modulation of interactions between specific factors and transcripts.

ACKNOWLEDGEMENTS

We thank A. E. McKee, N. G. Farny and M. J. Moore for their helpful comments and input in writing this manuscript. We apologize to our colleagues whose work we were unable to discuss because of space restrictions.

Footnotes

  • COMPETING INTERESTS

    The authors declare no competing financial interests.

REFERENCES

  1. ↵
    1. Abu-Baker, A and
    2. Rouleau, GA
    . (2007). Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies. Biochim. Biophys. Acta 1772, 173–185.
    OpenUrlPubMed
  2. ↵
    1. Alcazar-Roman, AR and
    2. Wente, SR
    . (2008). Inositol polyphosphates: a new frontier for regulating gene expression. Chromosoma 117, 1–13.
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    1. Alcazar-Roman, AR,
    2. Tran, EJ,
    3. Guo, S and
    4. Wente, SR
    . (2006). Inositol hexakisphosphate and Gle1 activate the DEAD-box protein Dbp5 for nuclear mRNA export. Nat. Cell Biol. 8, 711–716.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Amberg, DC,
    2. Goldstein, AL and
    3. Cole, CN
    . (1992). Isolation and characterization of RAT1: an essential gene of Saccharomyces cerevisiae required for the efficient nucleocytoplasmic trafficking of mRNA. Genes Dev. 6, 1173–1189.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Bentley, DL
    . (2005). Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors. Curr. Opin. Cell Biol. 17, 251–256.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Bousquet-Antonelli, C,
    2. Presutti, C and
    3. Tollervey, D
    . (2000). Identification of a regulated pathway for nuclear pre-mRNA turnover. Cell 102, 765–775.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Braun, IC,
    2. Rohrbach, E,
    3. Schmitt, C and
    4. Izaurralde, E
    . (1999). TAP binds to the constitutive transport element (CTE) through a novel RNA-binding motif that is sufficient to promote CTE-dependent RNA export from the nucleus. EMBO J. 18, 1953–1965.
    OpenUrlAbstract
  8. ↵
    1. Brodsky, AS and
    2. Silver, PA
    . (2000). Pre-mRNA processing factors are required for nuclear export. RNA 6, 1737–1749.
    OpenUrlAbstract
  9. ↵
    1. Burkard, KT and
    2. Butler, JS
    . (2000). A nuclear 3′-5′ exonuclease involved in mRNA degradation interacts with Poly(A) polymerase and the hnRNA protein Npl3p. Mol. Cell. Biol. 20, 604–616.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Chang, DD and
    2. Sharp, PA
    . (1989). Regulation by HIV Rev depends upon recognition of splice sites. Cell 59, 789–795.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Charlet, BN,
    2. Savkur, RS,
    3. Singh, G,
    4. Philips, AV,
    5. Grice, EA and
    6. Cooper, TA
    . (2002). Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol. Cell 10, 45–53.
    OpenUrlCrossRefPubMedWeb of Science
  12. ↵
    1. Cho, DH and
    2. Tapscott, SJ
    . (2007). Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim. Biophys. Acta 1772, 195–204.
    OpenUrlPubMed
  13. ↵
    1. Custodio, N,
    2. Carmo-Fonseca, M,
    3. Geraghty, F,
    4. Pereira, HS,
    5. Grosveld, F and
    6. Antoniou, M
    . (1999). Inefficient processing impairs release of RNA from the site of transcription. EMBO J. 18, 2855–2866.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Dansithong, W,
    2. Paul, S,
    3. Comai, L and
    4. Reddy, S
    . (2005). MBNL1 is the primary determinant of focus formation and aberrant insulin receptor splicing in DM1. J. Biol. Chem. 280, 5773–5780.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Das, B,
    2. Das, S and
    3. Sherman, F
    . (2006). Mutant LYS2 mRNAs retained and degraded in the nucleus of Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. USA 103, 10871–10876.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. de Haro, M,
    2. Al-Ramahi, I,
    3. De Gouyon, B,
    4. Ukani, L,
    5. Rosa, A,
    6. Faustino, NA,
    7. Ashizawa, T,
    8. Cooper, TA and
    9. Botas, J
    . (2006). MBNL1 and CUGBP1 modify expanded CUG-induced toxicity in a Drosophila model of myotonic dystrophy type 1. Hum. Mol. Genet. 15, 2138–2145.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Del Priore, V,
    2. Snay, CA,
    3. Bahr, A and
    4. Cole, CN
    . (1996). The product of the Saccharomyces cerevisiae RSS1 gene, identified as a high-copy suppressor of the rat7-1 temperature-sensitive allele of the RAT7/NUP159 nucleoporin, is required for efficient mRNA export. Mol. Biol. Cell 7, 1601–1621.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Eckner, R,
    2. Ellmeier, W and
    3. Birnstiel, ML
    . (1991). Mature mRNA 3′ end formation stimulates RNA export from the nucleus. EMBO J. 10, 3513–3522.
    OpenUrlPubMedWeb of Science
  19. ↵
    1. Farny, NG,
    2. Hurt, JA and
    3. Silver, PA
    . (2008). Definition of global and transcript-specific mRNA export pathways in metazoans. Genes Dev. 22, 66–78.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Feng, Y,
    2. Wente, SR and
    3. Majerus, PW
    . (2001). Overexpression of the inositol phosphatase SopB in human 293 cells stimulates cellular chloride influx and inhibits nuclear mRNA export. Proc. Natl. Acad. Sci. USA 98, 875–879.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Garcia-Lopez, A,
    2. Monferrer, L,
    3. Garcia-Alcover, I,
    4. Vicente-Crespo, M,
    5. Alvarez-Abril, MC and
    6. Artero, RD
    . (2008). Genetic and chemical modifiers of a CUG toxicity model in Drosophila. PLoS ONE 3, e1595.
    OpenUrl
  22. ↵
    1. Gatfield, D,
    2. Le Hir, H,
    3. Schmitt, C,
    4. Braun, IC,
    5. Kocher, T,
    6. Wilm, M and
    7. Izaurralde, E
    . (2001). The DExH/D box protein HEL/UAP56 is essential for mRNA nuclear export in Drosophila. Curr. Biol. 11, 1716–1721.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Guzik, BW,
    2. Levesque, L,
    3. Prasad, S,
    4. Bor, YC,
    5. Black, BE,
    6. Paschal, BM,
    7. Rekosh, D and
    8. Hammarskjold, ML
    . (2001). NXT1 (p15) is a crucial cellular cofactor in TAP-dependent export of intron-containing RNA in mammalian cells. Mol. Cell. Biol. 21, 2545–2554.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Hamm, J and
    2. Mattaj, IW
    . (1990). Monomethylated cap structures facilitate RNA export from the nucleus. Cell 63, 109–118.
    OpenUrlCrossRefPubMedWeb of Science
  25. ↵
    1. Hammell, CM,
    2. Gross, S,
    3. Zenklusen, D,
    4. Heath, CV,
    5. Stutz, F,
    6. Moore, C and
    7. Cole, CN
    . (2002). Coupling of termination, 3′ processing, and mRNA export. Mol. Cell. Biol. 22, 6441–6457.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Hieronymus, H and
    2. Silver, PA
    . (2003). Genome-wide analysis of RNA-protein interactions illustrates specificity of the mRNA export machinery. Nat. Genet. 33, 155–161.
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Hieronymus, H,
    2. Yu, MC and
    3. Silver, PA
    . (2004). Genome-wide mRNA surveillance is coupled to mRNA export. Genes Dev. 18, 2652–2662.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Hilleren, P,
    2. McCarthy, T,
    3. Rosbash, M,
    4. Parker, R and
    5. Jensen, TH
    . (2001). Quality control of mRNA 3′-end processing is linked to the nuclear exosome. Nature 413, 538–542.
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Holt, I,
    2. Mittal, S,
    3. Furling, D,
    4. Butler-Browne, GS,
    5. Brook, JD and
    6. Morris, GE
    . (2007). Defective mRNA in myotonic dystrophy accumulates at the periphery of nuclear splicing speckles. Genes Cells 12, 1035–1048.
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Jensen, TH,
    2. Boulay, J,
    3. Rosbash, M and
    4. Libri, D
    . (2001). The DECD box putative ATPase Sub2p is an early mRNA export factor. Curr. Biol. 11, 1711–1715.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    1. Johnson, C,
    2. Primorac, D,
    3. McKinstry, M,
    4. McNeil, J,
    5. Rowe, D and
    6. Lawrence, JB
    . (2000). Tracking COL1A1 RNA in osteogenesis imperfecta. splice-defective transcripts initiate transport from the gene but are retained within the SC35 domain. J. Cell Biol. 150, 417–432.
    OpenUrlAbstract/FREE Full Text
  32. ↵
    1. Kadowaki, T,
    2. Zhao, Y and
    3. Tartakoff, AM
    . (1992). A conditional yeast mutant deficient in mRNA transport from nucleus to cytoplasm. Proc. Natl. Acad. Sci. USA 89, 2312–2316.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Kapadia, F,
    2. Pryor, A,
    3. Chang, TH and
    4. Johnson, LF
    . (2006). Nuclear localization of poly(A)+ mRNA following siRNA reduction of expression of the mammalian RNA helicases UAP56 and URH49. Gene 384, 37–44.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Kendirgi, F,
    2. Rexer, DJ,
    3. Alcazar-Roman, AR,
    4. Onishko, HM and
    5. Wente, SR
    . (2005). Interaction between the shuttling mRNA export factor Gle1 and the nucleoporin hCG1: a conserved mechanism in the export of Hsp70 mRNA. Mol. Biol. Cell 16, 4304–4315.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Korey, CA,
    2. Wilkie, G,
    3. Davis, I and
    4. Van Vactor, D
    . (2001). small bristles is required for the morphogenesis of multiple tissues during Drosophila development. Genetics 159, 1659–1670.
    OpenUrlAbstract/FREE Full Text
  36. ↵
    1. Legrain, P and
    2. Rosbash, M
    . (1989). Some cis- and trans-acting mutants for splicing target pre-mRNA to the cytoplasm. Cell 57, 573–583.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Libri, D,
    2. Dower, K,
    3. Boulay, J,
    4. Thomsen, R,
    5. Rosbash, M and
    6. Jensen, TH
    . (2002). Interactions between mRNA export commitment, 3′-end quality control, and nuclear degradation. Mol. Cell. Biol. 22, 8254–8266.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Luna, R,
    2. Gaillard, H,
    3. Gonzalez-Aguilera, C and
    4. Aguilera, A
    . (2008). Biogenesis of mRNPs: integrating different processes in the eukaryotic nucleus. Chromosoma 117, 319–331.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Lund, MK and
    2. Guthrie, C
    . (2005). The DEAD-box protein Dbp5p is required to dissociate Mex67p from exported mRNPs at the nuclear rim. Mol. Cell 20, 645–651.
    OpenUrlCrossRefPubMedWeb of Science
  40. ↵
    1. Mankodi, A,
    2. Takahashi, MP,
    3. Jiang, H,
    4. Beck, CL,
    5. Bowers, WJ,
    6. Moxley, RT,
    7. Cannon, SC and
    8. Thornton, CA
    . (2002). Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol. Cell 10, 35–44.
    OpenUrlCrossRefPubMedWeb of Science
  41. ↵
    1. Mastroyiannopoulos, NP,
    2. Feldman, ML,
    3. Uney, JB,
    4. Mahadevan, MS and
    5. Phylactou, LA
    . (2005). Woodchuck post-transcriptional element induces nuclear export of myotonic dystrophy 3′ untranslated region transcripts. EMBO Rep. 6, 458–463.
    OpenUrlCrossRefPubMedWeb of Science
  42. ↵
    1. McKee, AE,
    2. Minet, E,
    3. Stern, C,
    4. Riahi, S,
    5. Stiles, CD and
    6. Silver, PA
    . (2005). A genome-wide in situ hybridization map of RNA-binding proteins reveals anatomically restricted expression in the developing mouse brain. BMC Dev. Biol. 5, 14.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Muhlemann, O,
    2. Mock-Casagrande, CS,
    3. Wang, J,
    4. Li, S,
    5. Custodio, N,
    6. Carmo-Fonseca, M,
    7. Wilkinson, MF and
    8. Moore, MJ
    . (2001). Precursor RNAs harboring nonsense codons accumulate near the site of transcription. Mol. Cell 8, 33–43.
    OpenUrlCrossRefPubMedWeb of Science
  44. ↵
    1. Murphy, R and
    2. Wente, SR
    . (1996). An RNA-export mediator with an essential nuclear export signal. Nature 383, 357–360.
    OpenUrlPubMed
  45. ↵
    1. Nakamura, T
    . (2005). NUP98 fusion in human leukemia: dysregulation of the nuclear pore and homeodomain proteins. Int. J. Hematol. 82, 21–27.
    OpenUrlCrossRefPubMedWeb of Science
  46. ↵
    1. Narkis, G,
    2. Ofir, R,
    3. Landau, D,
    4. Manor, E,
    5. Volokita, M,
    6. Hershkowitz, R,
    7. Elbedour, K and
    8. Birk, OS
    . (2007a). Lethal contractural syndrome type 3 (LCCS3) is caused by a mutation in PIP5K1C, which encodes PIPKI gamma of the phophatidylinsitol pathway. Am. J. Hum. Genet. 81, 530–539.
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    1. Narkis, G,
    2. Ofir, R,
    3. Manor, E,
    4. Landau, D,
    5. Elbedour, K and
    6. Birk, OS
    . (2007b). Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-kinase/Akt pathway. Am. J. Hum. Genet. 81, 589–595.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Nousiainen, HO,
    2. Kestila, M,
    3. Pakkasjarvi, N,
    4. Honkala, H,
    5. Kuure, S,
    6. Tallila, J,
    7. Vuopala, K,
    8. Ignatius, J,
    9. Herva, R and
    10. Peltonen, L
    . (2008). Mutations in mRNA export mediator GLE1 result in a fetal motoneuron disease. Nat. Genet. 40, 155–157.
    OpenUrlPubMed
  49. ↵
    1. Orengo, JP,
    2. Chambon, P,
    3. Metzger, D,
    4. Mosier, DR,
    5. Snipes, GJ and
    6. Cooper, TA
    . (2008). Expanded CTG repeats within the DMPK 3′ UTR causes severe skeletal muscle wasting in an inducible mouse model for myotonic dystrophy. Proc. Natl. Acad. Sci. USA 105, 2646–2651.
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. Pakkasjarvi, N,
    2. Kerosuo, L,
    3. Nousiainen, H,
    4. Gentile, M,
    5. Saharinen, J,
    6. Suhonen, S,
    7. Sariola, H,
    8. Peltonen, L,
    9. Kestila, M and
    10. Wartiovaara, K
    . (2007). Neural precursor cells from a fatal human motoneuron disease differentiate despite aberrant gene expression. Dev. Neurobiol. 67, 270–284.
    OpenUrlPubMed
  51. ↵
    1. Philips, AV,
    2. Timchenko, LT and
    3. Cooper, TA
    . (1998). Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 280, 737–741.
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Reed, R
    . (2003). Coupling transcription, splicing and mRNA export. Curr. Opin. Cell Biol. 15, 326–331.
    OpenUrlCrossRefPubMedWeb of Science
  53. ↵
    1. Reed, R and
    2. Cheng, H
    . (2005). TREX, SR proteins and export of mRNA. Curr. Opin. Cell Biol. 17, 269–273.
    OpenUrlCrossRefPubMedWeb of Science
  54. ↵
    1. Rehwinkel, J,
    2. Herold, A,
    3. Gari, K,
    4. Kocher, T,
    5. Rode, M,
    6. Ciccarelli, FL,
    7. Wilm, M and
    8. Izaurralde, E
    . (2004). Genome-wide analysis of mRNAs regulated by the THO complex in Drosophila melanogaster. Nat. Struct. Mol. Biol. 11, 558–566.
    OpenUrlCrossRefPubMedWeb of Science
  55. ↵
    1. Roughley, PJ,
    2. Rauch, F and
    3. Glorieux, FH
    . (2003). Osteogenesis imperfecta-clinical and molecular diversity. Eur. Cell. Mater. 5, 41–47; discussion 47.
    OpenUrlPubMed
  56. ↵
    1. Saguez, C,
    2. Olesen, JR and
    3. Jensen, TH
    . (2005). Formation of export-competent mRNP: escaping nuclear destruction. Curr. Opin. Cell Biol. 17, 287–293.
    OpenUrlCrossRefPubMedWeb of Science
  57. ↵
    1. Savkur, RS,
    2. Philips, AV and
    3. Cooper, TA
    . (2001). Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat. Genet. 29, 40–47.
    OpenUrlCrossRefPubMedWeb of Science
  58. ↵
    1. Smith, KP,
    2. Byron, M,
    3. Johnson, C,
    4. Xing, Y and
    5. Lawrence, JB
    . (2007). Defining early steps in mRNA transport: mutant mRNA in myotonic dystrophy type I is blocked at entry into SC-35 domains. J. Cell Biol. 178, 951–964.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    1. Sommer, P and
    2. Nehrbass, U
    . (2005). Quality control of messenger ribonucleoprotein particles in the nucleus and at the pore. Curr. Opin. Cell Biol. 17, 294–301.
    OpenUrlCrossRefPubMedWeb of Science
  60. ↵
    1. Stover, ML,
    2. Primorac, D,
    3. Liu, SC,
    4. McKinstry, MB and
    5. Rowe, DW
    . (1993). Defective splicing of mRNA from one COL1A1 allele of type I collagen in nondeforming (type I) osteogenesis imperfecta. J. Clin. Invest. 92, 1994–2002.
    OpenUrlCrossRefPubMed
  61. ↵
    1. Strasser, K and
    2. Hurt, E
    . (2001). Splicing factor Sub2p is required for nuclear mRNA export through its interaction with Yra1p. Nature 413, 648–652.
    OpenUrlCrossRefPubMed
  62. ↵
    1. Stutz, F,
    2. Bachi, A,
    3. Doerks, T,
    4. Braun, IC,
    5. Seraphin, B,
    6. Wilm, M,
    7. Bork, P and
    8. Izaurralde, E
    . (2000). REF, an evolutionary conserved family of hnRNP-like proteins, interacts with TAP/Mex67p and participates in mRNA nuclear export. RNA 6, 638–650.
    OpenUrlAbstract
  63. ↵
    1. van Deursen, J,
    2. Boer, J,
    3. Kasper, L and
    4. Grosveld, G
    . (1996). G2 arrest and impaired nucleocytoplasmic transport in mouse embryos lacking the proto-oncogene CAN/Nup214. EMBO J. 15, 5574–5583.
    OpenUrlPubMedWeb of Science
  64. ↵
    1. Verbsky, J,
    2. Lavine, K and
    3. Majerus, PW
    . (2005). Disruption of the mouse inositol 1,3,4,5,6-pentakisphosphate 2-kinase gene, associated lethality, and tissue distribution of 2-kinase expression. Proc. Natl. Acad. Sci. USA 102, 8448–8453.
    OpenUrlAbstract/FREE Full Text
  65. ↵
    1. Watkins, JL,
    2. Murphy, R,
    3. Emtage, JL and
    4. Wente, SR
    . (1998). The human homologue of Saccharomyces cerevisiae Gle1p is required for poly(A)+ RNA export. Proc. Natl. Acad. Sci. USA 95, 6779–6784.
    OpenUrlAbstract/FREE Full Text
  66. ↵
    1. Weirich, CS,
    2. Erzberger, JP,
    3. Flick, JS,
    4. Berger, JM,
    5. Thorner, J and
    6. Weis, K
    . (2006). Activation of the DExD/H-box protein Dbp5 by the nuclear-pore protein Gle1 and its coactivator InsP6 is required for mRNA export. Nat. Cell Biol. 8, 668–676.
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    1. Wheeler, TM and
    2. Thornton, CA
    . (2007). Myotonic dystrophy: RNA-mediated muscle disease. Curr. Opin. Neurol. 20, 572–576.
    OpenUrlCrossRefPubMedWeb of Science
  68. ↵
    1. Williams, BJ,
    2. Boyne, JR,
    3. Goodwin, DJ,
    4. Roaden, L,
    5. Hautbergue, GM,
    6. Wilson, SA and
    7. Whitehouse, A
    . (2005). The prototype gamma-2 herpesvirus nucleocytoplasmic shuttling protein, ORF 57, transports viral RNA through the cellular mRNA export pathway. Biochem. J. 387, 295–308.
    OpenUrlCrossRefPubMedWeb of Science
  69. ↵
    1. York, JD
    . (2006). Regulation of nuclear processes by inositol polyphosphates. Biochim. Biophys. Acta 1761, 552–559.
    OpenUrlPubMed
  70. ↵
    1. York, JD,
    2. Odom, AR,
    3. Murphy, R,
    4. Ives, EB and
    5. Wente, SR
    . (1999). A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export. Science 285, 96–100.
    OpenUrlAbstract/FREE Full Text
  71. ↵
    1. Zenklusen, D,
    2. Vinciguerra, P,
    3. Wyss, JC and
    4. Stutz, F
    . (2002). Stable mRNP formation and export require cotranscriptional recruitment of the mRNA export factors Yra1p and Sub2p by Hpr1p. Mol. Cell. Biol. 22, 8241–8253.
    OpenUrlAbstract/FREE Full Text
  72. ↵
    1. Zhang, Z,
    2. Lotti, F,
    3. Dittmar, K,
    4. Younis, I,
    5. Wan, L,
    6. Kasim, M and
    7. Dreyfuss, G
    . (2008). SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 133, 585–600.
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
Previous ArticleNext Article
Back to top
Previous ArticleNext Article

This Issue

 Download PDF

Email

Thank you for your interest in spreading the word on Disease Models & Mechanisms.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
mRNA nuclear export and human disease
(Your Name) has sent you a message from Disease Models & Mechanisms
(Your Name) thought you would like to see the Disease Models & Mechanisms web site.
Share
mRNA nuclear export and human disease
Jessica A. Hurt, Pamela A. Silver
Disease Models & Mechanisms 2008 1: 103-108; doi: 10.1242/dmm.000745
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
mRNA nuclear export and human disease
Jessica A. Hurt, Pamela A. Silver
Disease Models & Mechanisms 2008 1: 103-108; doi: 10.1242/dmm.000745

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Alerts

Please log in to add an alert for this article.

Sign in to email alerts with your email address

Article navigation

  • Top
  • Article
    • Abstract
    • Model organisms have provided the framework for our understanding of mRNA export
    • Defects in mRNA export can result in human disease
    • Can tissue-specific effects result from mutations in a core export factor?
    • ACKNOWLEDGEMENTS
    • Footnotes
    • REFERENCES
  • Figures & tables
  • Info & metrics
  • PDF

Related articles

Cited by...

More in this TOC section

  • Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
  • Fibrodysplasia ossificans progressiva: mechanisms and models of skeletal metamorphosis
  • Role of resting metabolic rate and energy expenditure in hunger and appetite control: a new formulation
Show more Commentary

Similar articles

Other journals from The Company of Biologists

Development

Journal of Cell Science

Journal of Experimental Biology

Biology Open

Advertisement

Editor’s Choice – Altered expression of the Cdk5 activator-like protein, Cdk5α, causes neurodegeneration, in part by accelerating the rate of aging

By developing a comprehensive and quantitative metric for physiological age of Drosophila, Edward Giniger and colleagues show that a neurodegeneration mutant produces its effects in part by accelerating the absolute rate of aging.


First Person interviews 

Have you seen our interviews with the early-career first authors of our papers? Recently, we caught up with first authors Sarah Foriel, Henna Myllymäki and Mirja Niskanen, Wenqing Zhou, Rifdat Aoidi and Amy Irving.


Review – Metastasis in context: modeling the tumor microenvironment with cancer-on-a-chip approaches

In a new Review article, Jaap M. J. den Toonder and colleagues evaluate the recent contributions of cancer-on-a-chip models to our understanding of the tumor microenvironment and its role in the onset of metastasis. The authors also provide an outlook for future applications of this emerging technology.


DMM Conference Travel Grants

Are you an early career scientist with plans to attend a scientific meeting, conference, workshop or course relating to the areas of research covered by DMM? The next round of applications for DMM Conference Travel Grants closes on 4 May 2018. Find out more here and get your application in soon.


Why should you publish your next paper in DMM?

DMM aims to promote human health by encouraging collaboration between basic and clinical researchers, covering a diverse range of diseases, approaches and models. Our Editors are all active researchers in the field – your peers, colleagues and mentors, who know how much work has gone into every paper. Recently, we have introduced format-free submission, and we accept peer review reports from other journals, making submission as easy as possible for our authors. Send us your next great paper – publish with us and you'll be in good company.

Articles

  • Accepted manuscripts
  • Issue in progress
  • Latest complete issue
  • Issue archive
  • Archive by article type
  • Subject collections
  • Interviews
  • Alerts

About us

  • About DMM
  • Editors and Board
  • Editor biographies
  • Travelling Fellowships
  • Grants and funding
  • Workshops and Meetings
  • The Company of Biologists

For Authors

  • Submit a manuscript
  • Aims and scope
  • Presubmission enquiries
  • Article types
  • Manuscript preparation
  • Cover suggestions
  • Editorial process
  • Promoting your paper
  • Open Access
  • Biology Open transfer

Journal Info

  • Journal policies
  • Rights and permissions
  • Media policies
  • Reviewer guide
  • Alerts

Contact

  • Contact DMM
  • Advertising
  • Feedback

Twitter   YouTube   LinkedIn

© 2018   The Company of Biologists Ltd   Registered Charity 277992